Clinical Trials Browser

Terminated × Recurrence × obinutuzumab × Clear all

NCT05896163 2026-05-06

MAPtivate-6

Phase 1/2 Terminated

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04464798 2025-04-29

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Phase 1 Terminated

Lymphoma, Recurrence